Award details

Development of serotype-cross-reactive sub-unit vaccines for African horse sickness and bluetongue viruses

Reference	BBS/E/I/00001455
Principal Investigator / Supervisor	Professor Peter Mertens
Co-Investigators / Co-Supervisors
Institution	The Pirbright Institute
Department	The Pirbright Institute Department
Funding type	Research
Value (£)	106,544
Status	Completed
Type	Institute Project
Start date	01/07/2009
End date	30/06/2010
Duration	12 months

Abstract

The project will continue and extend previous studies that involved the development of recombinant Modified Vaccinia Ankara (MVA) strains expressing individual proteins of African horse sickness virus (AHSV), to explore their potential as vaccine components for different AHSV serotypes. These studies have previously shown induction of virus neutralizing antibodies in ponies, following vaccination with MVA expressing AHSV-4 VP2. In particular we are interested in understanding the nature of cross-reactive neutralizing-antibody and protective-immune responses. The project primarily involves working with AHSV proteins expressed in MVA, baculovirus and/or bacterial expression systems as potential vaccine components. Initial vaccination efficacy studies will be carried out in a mouse model system, involving collaboration with Javier Ortego at Valdeolmos in Spain.

Summary

unavailable

Committee	Not funded via Committee
Research Topics	Animal Health, Immunology, Microbiology
Research Priority	X – Research Priority information not available
Research Initiative	X - not in an Initiative
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search